UniProt P49841
Glycogen synthase kinase-3 beta (P49841)
Glycogen synthase kinase-3 beta (UniProt P49841), EC 2.7.11.1, 2.7.11.26: 165 experimental structures and 1 predicted model on GenesisL1, 31 ligands bound, 30 pockets. Binding sites, druggability and experiment against prediction…
- UniProt
- P49841
- Protein
- Glycogen synthase kinase-3 beta
- EC
- 2.7.11.1, 2.7.11.26
- Experimental structures
- 165
- Predicted models
- 1
- Ligands
- 31
- Pockets
- 30 · 5 records with a druggable one
Structures
166 records of P49841 in the MolNFT archive: 165 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1GNG | Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide | x-ray diffraction | A, B | — | — |
| 1GNG | Glycogen synthase kinase-3 beta (GSK3) complex with frattide peptide | x-ray diffraction | A, B | — | — |
| 1H8F | Glycogen Synthase Kinase 3 beta. | x-ray diffraction | A, B | — | — |
| 1H8F | Glycogen synthase kinase 3 beta. | x-ray diffraction | A, B | — | — |
| 1I09 | Structure of glycogen synthase kinase-3 (GSK3B) | x-ray diffraction | A, B | — | — |
| 1I09 | Structure of glycogen synthase kinase-3 (GSK3B) | x-ray diffraction | A, B | — | — |
| 1J1B | Binary complex structure of human tau protein kinase I with AMPPNP | x-ray diffraction | A, B | — | — |
| 1J1B | Binary complex structure of human tau protein kinase I with amppnp | x-ray diffraction | A, B | — | — |
| 1J1C | Binary complex structure of human tau protein kinase I with ADP | x-ray diffraction | A, B | — | — |
| 1J1C | Binary complex structure of human tau protein kinase I with ADP | x-ray diffraction | A, B | — | — |
| 1O6K | Structure of activated form of PKB kinase domain S474D with GSK3 peptide and AMP-PNP | x-ray diffraction | C | — | — |
| 1O6K | Structure of activated form of pkb kinase domain S474D with GSK3 peptide and AMP-pnp | x-ray diffraction | C | — | — |
| 1O6L | Crystal structure of an activated Akt/protein kinase B (PKB-PIF chimera) ternary complex with… | x-ray diffraction | C | — | — |
| 1O6L | Crystal structure of an activated AKT/PROTEIN kinase B (pkb-pif chimera) ternary complex with… | x-ray diffraction | C | — | — |
| 1O9U | Glycogen synthase kinase 3 beta complexed with axin peptide | x-ray diffraction | A | — | — |
| 1O9U | Glycogen synthase kinase 3 beta complexed with axin peptide | x-ray diffraction | A | — | — |
| 1PYX | GSK-3 Beta complexed with AMP-PNP | x-ray diffraction | A, B | — | — |
| 1PYX | Gsk-3 beta complexed with AMP-pnp | x-ray diffraction | A, B | — | — |
| 1Q3D | GSK-3 Beta complexed with Staurosporine | x-ray diffraction | A, B | — | — |
| 1Q3D | Gsk-3 beta complexed with staurosporine | x-ray diffraction | A, B | — | — |
| 1Q3W | GSK-3 Beta complexed with Alsterpaullone | x-ray diffraction | A, B | — | — |
| 1Q3W | Gsk-3 beta complexed with alsterpaullone | x-ray diffraction | A, B | — | — |
| 1Q41 | GSK-3 Beta complexed with Indirubin-3'-monoxime | x-ray diffraction | A, B | — | — |
| 1Q41 | Gsk-3 beta complexed with indirubin-3'-monoxime | x-ray diffraction | A, B | — | — |
| 1Q4L | GSK-3 Beta complexed with Inhibitor I-5 | x-ray diffraction | A, B | — | — |
| 1Q4L | Gsk-3 beta complexed with inhibitor I-5 | x-ray diffraction | A, B | — | — |
| 1Q5K | crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor | x-ray diffraction | A, B | — | — |
| 1Q5K | Crystal structure of glycogen synthase kinase 3 in complexed with inhibitor | x-ray diffraction | A, B | — | — |
| 1R0E | Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor | x-ray diffraction | A, B | — | — |
| 1R0E | Glycogen synthase kinase-3 beta in complex with 3-indolyl-4- arylmaleimide inhibitor | x-ray diffraction | A, B | — | — |
| 1UV5 | Glycogen synthase kinase 3 beta complexed with 6-bromoindirubin-3'-oxime | x-ray diffraction | A | — | — |
| 1UV5 | Glycogen synthase kinase 3 beta complexed with 6-bromoindirubin-3'- oxime | x-ray diffraction | A | — | — |
| 2JDO | Structure of pkb-beta (AKT2) complexed with isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)… | x-ray diffraction | C | — | — |
| 2JDO | Structure of pkb-beta (AKT2) complexed with isoquinoline-5- sulfonic acid (2-(2-(4-chlorobenzyloxy)… | x-ray diffraction | C | — | — |
| 2JDR | Structure of pkb-beta (AKT2) complexed with the inhibitor a-443654 | x-ray diffraction | C | — | — |
| 2JDR | Structure of pkb-beta (AKT2) complexed with the inhibitor a- 443654 | x-ray diffraction | C | — | — |
| 2JLD | Extremely Tight Binding of Ruthenium Complex to Glycogen Synthase Kinase 3 | x-ray diffraction | A, B | — | — |
| 2JLD | Extremely tight binding of ruthenium complex to glycogen synthase kinase 3 | x-ray diffraction | A, B | — | — |
| 2O5K | Crystal Structure of GSK3beta in complex with a benzoimidazol inhibitor | x-ray diffraction | A | — | — |
| 2O5K | Crystal structure of GSK3BETA in complex with a benzoimidazol inhibitor | x-ray diffraction | A | — | — |
| 2OW3 | Glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor | x-ray diffraction | A, B | — | — |
| 2OW3 | Glycogen synthase kinase-3 beta in complex with bis-(INDOLE)MALEIMIDE pyridinophane inhibitor | x-ray diffraction | A, B | — | — |
| 2UW9 | STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-chloro-phenyl)-4-(4-(1H-pyrazol-4-yl)-phenyl)-piper… | x-ray diffraction | C | — | — |
| 2UW9 | Structure of pkb-beta (AKT2) complexed with 4-(4-chloro… | x-ray diffraction | C | — | — |
| 2X39 | Structure of 4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin… | x-ray diffraction | C | — | — |
| 2X39 | Structure of 4-amino-N-(4-chlorobenzyl)-1-(7H-PYRROLO(2,3-D)… | x-ray diffraction | C | — | — |
| 2XH5 | Structure of 4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4- yl)piperidin-4-amine bound to… | x-ray diffraction | C | — | — |
| 2XH5 | Structure of 4-(4-tert-butylbenzyl)-1-(7H-PYRROLO(2,3-D) pyrimidin-4-YL)PIPERIDIN-4-amine bound to… | x-ray diffraction | C | — | — |
| 3CQU | Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor | x-ray diffraction | C | — | — |
| 3CQU | Crystal structure of AKT-1 complexed with substrate peptide and inhibitor | x-ray diffraction | C | — | — |
| 3CQW | Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor | x-ray diffraction | C | — | — |
| 3CQW | Crystal structure of AKT-1 complexed with substrate peptide and inhibitor | x-ray diffraction | C | — | — |
| 3DU8 | Crystal structure of GSK-3 beta in complex with NMS-869553A | x-ray diffraction | A, B | — | — |
| 3DU8 | Crystal structure of gsk-3 beta in complex with nms-869553A | x-ray diffraction | A, B | — | — |
| 3E87 | Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors | x-ray diffraction | C, D | — | — |
| 3E87 | Crystal structures of the kinase domain of AKT2 in complex with ATP- competitive inhibitors | x-ray diffraction | C, D | — | — |
| 3E88 | Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors | x-ray diffraction | C, D | — | — |
| 3E88 | Crystal structures of the kinase domain of AKT2 in complex with ATP- competitive inhibitors | x-ray diffraction | C, D | — | — |
| 3E8D | Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors | x-ray diffraction | C, D | — | — |
| 3E8D | Crystal structures of the kinase domain of AKT2 in complex with ATP- competitive inhibitors | x-ray diffraction | C, D | — | — |
106 records more on the page itself.
Ligands
- CL · Chloride ion · in 12 records
- SO4 · Sulfate ion · in 5 records
- 6VL · (4~{S})-4-ethyl-7,7-dimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one · in 4 records
- 39I · ~{N}4-(3-cyclopropyl-1~{H}-pyrazol-5-yl)-~{N}2-(phenylmethyl)thieno[3,2-d]pyrimidine-2,4-diamine · in 2 records
- 6QH · 5-(3-chloranyl-4-methoxy-phenyl)-~{N}-[3-(1,2,4-triazol-1-yl)propyl]-1,3-oxazole-4-carboxamide · in 2 records
- 6VK · (4~{S})-3-cyclopropyl-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one · in 2 records
- 6VM · (4~{S})-3-(2,2-dimethylpropyl)-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one · in 2 records
- F1B · (3~{Z})-5-ethanoyl-3-[[(1-methylpiperidin-4-yl)amino]-phenyl-methylidene]-1~{H}-indol-2-one · in 2 records
- F4N · ~{N}-[(~{E})-(6-bromanylimidazo[1,2-a]pyridin-3-yl) methylideneamino]-~{N},2-dimethyl-5-nitro-benzenesulfonamide · in 2 records
- FKB · (2~{R})-3-[7-azanyl-5-(cyclohexylamino)-[1,2, 4]triazolo[1,5-a][1,3,5]triazin-2-yl]-2-cyano-propanamide · in 2 records
- G8B · 3-azanyl-~{N}-(2-methoxyphenyl)-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrazine-2-carboxamide · in 2 records
- G8E · 3-azanyl-6-(4-morpholin-4-ylsulfonylphenyl)-~{N}-pyridin-3-yl-pyrazine-2-carboxamide · in 2 records
- NA · Sodium ion · in 2 records
- 3UO · 2-[(cyclopropylcarbonyl)amino]-N-(4-methoxypyridin-3-yl)pyridine-4-carboxamide · in 1 record
- 3UP · 2-[(cyclopropylcarbonyl)amino]-N-(4-phenylpyridin-3-yl)pyridine-4-carboxamide · in 1 record
- 65A · 4-(2-methoxyphenyl)-3,7,7-trimethyl-1,6,7,8-tetrahydro-5H-pyrazolo[3,4-b]quinolin-5-one · in 1 record
- 65C · Chir99021 · in 1 record
- B4K · ~{N}-[6-[3,4-bis(oxidanyl)phenyl]-1~{H}-pyrazolo[3,4-b]pyridin-3-yl]ethanamide · in 1 record
- D1E · (4S,5R,8R)-4-ethyl-8-fluoro-4-[3-(3-fluoro-5-methoxypyridin-4-yl)phenyl]-7,7-dimethyl-4,5,6,7,8,9-hexahydro-2H-pyrazolo[3,4-b]quinolin-5-ol · in 1 record
- G8N · 3-azanyl-~{N}-(2-methoxyethyl)-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrazine-2-carboxamide · in 1 record
- L7C · (3R)-1-[3-(2-fluorophenyl)propanoyl]-N-(pyridin-2-yl) pyrrolidine-3-carboxamide · in 1 record
- L7I · 5-(4-fluorophenyl)-4-[1-(methanesulfonyl)azetidin-3-yl]pyrimidin-2-amine · in 1 record
- L7R · 3-[2-amino-5-(4-fluorophenyl)pyrimidin-4-yl]-N,N-dimethylazetidine-1-sulfonamide · in 1 record
- L7W · (3S)-1-[(2-fluorophenoxy)acetyl]-N-(pyridin-2-yl) pyrrolidine-3-carboxamide · in 1 record
- N1Q · 5-[2,3-bis(fluoranyl)phenyl]-~{N}-[[1-(2-methoxyethyl) piperidin-4-yl]methyl]-1~{H}-indazole-3-carboxamide · in 1 record
- O9L · 2-pyridin-3-yl-8-thiomorpholin-4-yl-[1,3]oxazolo[5,4-f]quinoxaline · in 1 record
- OH8 · ~{N}-[[1-(2-methoxyethyl)piperidin-4-yl]methyl]-5-(5-propan-2-yloxypyridin-3-yl)-1~{H}-indazole-3-carboxamide · in 1 record
- OHK · ~{N}-(oxan-4-ylmethyl)-6-(5-propan-2-yloxypyridin-3-yl)imidazo[1,5-a]pyridine-3-carboxamide · in 1 record
- PO4 · Phosphate ion · in 1 record
- QQA · 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl) amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one · in 1 record
Experiment against prediction
- 6GN1 chain A against the predicted model P49841: TM-score 0.99, RMSD 0.52 Å
- 6GN1 chain B against the predicted model P49841: TM-score 0.99, RMSD 0.52 Å
- 3DU8 chain A against the predicted model P49841: TM-score 0.99, RMSD 0.51 Å
- 4PTG chain A against the predicted model P49841: TM-score 0.99, RMSD 0.51 Å
- 3SAY chain A against the predicted model P49841: TM-score 0.99, RMSD 0.55 Å
- 3SAY chain B against the predicted model P49841: TM-score 0.99, RMSD 0.57 Å
- 3L1S chain B against the predicted model P49841: TM-score 0.99, RMSD 0.54 Å
- 4IQ6 chain B against the predicted model P49841: TM-score 0.99, RMSD 0.54 Å
- 1PYX chain B against the predicted model P49841: TM-score 0.99, RMSD 0.60 Å
- 3L1S chain A against the predicted model P49841: TM-score 0.99, RMSD 0.59 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.